The latest news about Montara

Montara Therapeutics awarded $3.3 million non-dilutive MJFF grant to develop BrainOnly™ Parkinson’s therapy targeting LRRK2, a genetically validated target with major drug development challenges. New collaboration to use Montara’s BrainOnly platform to create a next-generation brain-selective LRRK2 inhibitor that avoids the irreversible toxicity from unselective peripheral activity.

Syndicate strengthened with new investors and increased commitments from all existing investors. Total Series Seed funding reaches $28M to advance lead epilepsy program to IND, progress neurodegeneration program to development candidate (DC), and accelerate a third undisclosed program. Troy Wilson joins as Chairman of the Board, bringing extensive leadership, operating, and financing experience.

This Endpoints News article explores the creation of Montara Therapeutics by Kevan Shokat and Nicholas Hertz after selling their first neuro startup to AbbVie.

Montara Therapeutics, Inc. (‘Montara’), a therapeutics company aiming to revolutionize the discovery and development of brain-targeting drugs, announced today the closing of an oversubscribed $8 million seed financing led by SV Health Investors’ Dementia Discovery Fund and co-lead Two Bear Capital. Dolby Family Ventures and KdT Ventures also participated in the round.